Blind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma.
Open Access
- 1 April 1983
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 67 (4), 216-219
- https://doi.org/10.1136/bjo.67.4.216
Abstract
The results of a 12-month blind randomised trial comparing the intraocular pressure lowering effect of timolol 0.25% with timolol 0.5% are presented. 27% of patients (22% of eyes) required additional antiglaucoma medication after a minimum time interval of 6 months to maintain an intraocular pressure less than 23 mmHg. The mean reduction in intraocular pressure (from pretreatment values) at 12 months was 24% for eyes treated with timolol 0.25% and 19% for eyes treated with timolol 0.5%. When reductions in intraocular pressure at each follow-up interval were statistically significant (timolol 0.25% treated eyes compared with timolol 0.5% treated eyes), the significance always favoured timolol 0.25%.This publication has 14 references indexed in Scilit:
- The Place of Timolol in the Practice of OphthalmologyOphthalmology, 1980
- Timolol MaleateArchives of Ophthalmology (1950), 1979
- Timolol and EpinephrineArchives of Ophthalmology (1950), 1979
- Influences on the density of beta-adrenergic receptors in the cornea and iris--ciliary body of the rabbit.1978
- The Mechanism of Timolol in Lowering Intraocular PressureArchives of Ophthalmology (1950), 1978
- Long-Term Experience with Timolol Ophthalmic Solution in Patients with Open-Angle GlaucomaOphthalmology, 1978
- TIMOLOL - HYPOTENSIVE EFFECT, USED ALONE AND IN COMBINATION FOR TREATMENT OF INCREASED INTRA-OCULAR PRESSURE1978
- TimololArchives of Ophthalmology (1950), 1977
- TimololArchives of Ophthalmology (1950), 1977
- Timolol maleate, a new beta-adrenergic receptor blocking agent.1975